Inhalation Home

The only technical publication devoted exclusively to readers involved in development
and production of pulmonary or nasal delivered pharmaceuticals.

Inhalation Home

Article Archive

Browse by Subject Browse by Organization Browse by Author

Cross Industry Organizations
Tablets & Capsules
INH Magazine

Cover Photo Courtesy of
Astech Projects

Download Table of Contents

This Month’s Focus: Quality/Compliance

Respirable, engineered, spray-dried dry powders for 505(b)(2) drug product development

Spray-dry manufacturing is amenable to a variety of compound chemistries and may be a useful tool for the development of inhalation drug products that pursue the US FDA’s 505(b)(2) submission pathway.

An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 2—Informative chapters <1601>, <1602>, <1603> and <1604>

This is the second article of a two-part series that provides an overview of the work currently undertaken by members of the Aerosols Sub-Committee at the USP. It focuses on recent updates to the informative chapters within the committee’s remit.

An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 1—Normative chapters <5>, <601>, <602>, <603> and <604>

This is the first article of a two-part series that provides an overview of the work currently undertaken by members of the Aerosols Sub-Committee at the USP. It focuses on recent updates to the normative chapters within the committee’s remit.

General Features

Back Page: The pediatric asthma yardstick

This new guideline provides recommendations to determine how and when to step up treatment of uncontrolled asthma.

Cross-Industry Organizations: ISAM: 2018 highlights and a preview of the 2019 Congress

ISAM engages its members through educational resources and events, including the biannual ISAM Congress.

Previewing Drug Delivery Partnerships 2019

Drug Delivery Partnerships 2019 will be held January 28-30, 2019 at the PGA National Resort & Spa in Palm Beach Gardens, Florida, US.

February Content

Defining the dosage strength for labeling of DPIs: Use, limitations and relevance of in-vitro data

Point of View: Recommendations to a young scientist for pursuing inhalation research

Back Page: The return of Primatene Mist

Cross-Industry Organizations: IPAC-RS

A preview of RDD Europe 2019

Issue Focuses

January: Reference and Buyer’s Resource

February: Product Development/ Contract Testing

April: Instruments

June: Nasal Delivery/Nebulizers

August: Particle Characterization

October: Devices

December: Quality/Compliance

Contact the editor:
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
Fax 651-287-5650

Inhalation Article Guidelines

Technical article requirements

The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.

All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner.

The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.

We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.

Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.

Editorial board review and production

All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.

Special Sections
Reference & Buyer’s Resource
Product Development/
Contract Testing
Formulation Development/
Nasal Delivery/Nebulizers
Particle Characterization
Particle Manufacturing
Outsourcing Services
Buyers Guide
Inhalation 1-2-3